Page last updated: 2024-10-30

losartan and Cardiac Remodeling, Ventricular

losartan has been researched along with Cardiac Remodeling, Ventricular in 79 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research Excerpts

ExcerptRelevanceReference
"This study, although underpowered, suggests that neither enalapril nor losartan was superior as compared with each other for left ventricular remodeling after myocardial infarction; however, powerful evidence of equivalence was not provided."9.10Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction. ( Baggi, JM; Brandi, JM; Cordeiro, JA; de Godoy, MF; Joaquim, MR; Maia, LN; Nicolau, JC; Santos, M; Vítola, JV, 2003)
"A total of 754 hypertensive patients with left ventricular hypertrophy (LVH) by Cornell voltage-duration product or Sokolow-Lyon voltage criteria on a screening electrocardiogram had their LV mass measured by echocardiogram at enrolment in the Losartan Intervention For Endpoint Reduction (LIFE) trial, and after 12 and 24 months of blinded therapy with losartan-based or atenolol-based regimens."9.10Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Liu, JE; Nieminen, MS; Palmieri, V; Papademetriou, V; Wachtell, K, 2002)
"To evaluate effectiveness of nonpeptide angiotensin-2 subtype-1 receptor antagonist losartan in therapy of symptomatic congestive heart failure in patients with ischemic heart disease, 116 patients were examined at the age of 36-62 (mean age 50."9.09[Losartan in therapy of chronic heart failure]. ( Berezin, AE; Vizir, VA, 2000)
"Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI)."7.91Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. ( Ahmad, M; Leenen, FHH; Llorens-Cortes, C; Marc, Y, 2019)
"Treatment with the selective VDR activator paricalcitol reduces myocardial fibrosis and preserves diastolic LV function due to pressure overload in a mouse model."7.78The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. ( Cannon, MV; de Boer, RA; Mahmud, H; Meems, LM; Ruifrok, WP; Silljé, HH; van Gilst, WH; Voors, AA, 2012)
"This study tested the reversal of subcellular remodelling in heart failure due to myocardial infarction (MI) upon treatment with losartan, an angiotensin II receptor antagonist."7.78Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction. ( Babick, A; Chapman, D; Dhalla, NS; Elimban, V; Zieroth, S, 2012)
"We investigated in Lewis normotensive rats the effect of coronary artery ligation on the expression of cardiac angiotensin-converting enzymes (ACE and ACE 2) and angiotensin II type-1 receptors (AT1a-R) 28 days after myocardial infarction."7.72Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. ( Averill, DB; Brosnihan, KB; Ferrario, CM; Gallagher, PE; Ishiyama, Y; Tallant, EA, 2004)
"This study was carried out to investigate the effects of early administration of losartan on ventricular remodelling (VR) in rabbits with experimental myocardial infarction (MI)."7.72[Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction]. ( Depetris Chauvin, A; Gelpi, RJ; González, GE; Mangas, F; Morales, C; Palleiro, J; Rodríguez, M, 2004)
"It has been verified that losartan has beneficial effects on ventricular remodeling (VRM) after acute myocardial infarction (AMI), but the effects of carvedilol alone or in combination with losartan on this condition have not been defined."7.72Comparative effects of carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats. ( Chen, JL; Chen, ZJ; Gao, RL; Ruan, YM; Tang, YD; Wang, PH; Yang, YJ; Zhang, P; Zhou, YW, 2003)
"To compare the effects of carvedilol, losartan and their combination in preventing from left ventricular remodeling (LVRM) after acute myocardial infarction(AMI) in rats."7.71[Comparative effects of carvedilol, losartan and their combination in preventing left ventricular remodeling after acute myocardial infarction in rats]. ( Chen, Z; Gao, R; Li, Y; Ruan, Y; Tang, Y; Yang, Y, 2001)
"To investigate effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in the spontaneously hypertensive rats (SHR)."7.71[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats]. ( He, BX; Liang, XQ; Yu, GL, 2001)
"The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure."7.71Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. ( Ellingsen, O; Falck, G; Loennechen, JP; Wisløff, U, 2002)
"To compare the effects of losartan, enalapril and their combination in the prevention of left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in the rat."7.71Comparison of the effects of losartan, enalapril and their combination in the prevention of left ventricular remodeling after acute myocardial infarction in the rat. ( Laifeng, S; Pei, Z; Xinglin, X; Yanwen, Z; Yi, T; Yingmao, R; Yishu, X; Yongli, L; Yuejin, Y; Zaijia, C, 2002)
"To determine the effects of losartan and captopril treatment on ventricular remodeling and function after myocardial infarction in rats."7.70Comparative effects of losartan and captopril on ventricular remodeling and function after myocardial infarction in the rat. ( Chen, H; Pan, W; Pu, S; Shen, X; Yang, Y; Zhang, G, 1998)
"We examined the effect of losartan on ventricular remodeling after AMI comparatively with that of enalapril."6.71Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction. ( Hanada, H; Higuma, T; Ishizaka, H; Maeda, N; Matsunaga, T; Mori, Y; Okumura, K; Onodera, H; Osanai, T; Sasaki, S; Tamura, Y; Yoshimachi, F, 2005)
"Metoprolol treatment for 2 weeks improved LV systolic function."5.35Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction. ( Kerkelä, R; Kubin, AM; Leskinen, H; Pieviläinen, O; Ruskoaho, H; Serpi, R; Soini, Y; Tenhunen, O; Tolonen, AM; Vaskivuo, T, 2009)
"9 years-old, with stage I hypertension at baseline and after 18 months of treatment with chlorthalidone/amiloride or losartan."5.27Echocardiographic Left Ventricular Reverse Remodeling After 18 Months of Antihypertensive Treatment in Stage I Hypertension. Results From the Prever-Treatment Study. ( Bertoluci, C; Branchi, TV; Foppa, M; Fuchs, FD; Fuchs, SC; Santos, ABS, 2018)
"Prospective cohort substudy of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) randomized clinical trial, conducted from 1995 to 2001."5.11Prognostic significance of left ventricular mass change during treatment of hypertension. ( Aurup, P; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Harris, K; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004)
"This study, although underpowered, suggests that neither enalapril nor losartan was superior as compared with each other for left ventricular remodeling after myocardial infarction; however, powerful evidence of equivalence was not provided."5.10Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction. ( Baggi, JM; Brandi, JM; Cordeiro, JA; de Godoy, MF; Joaquim, MR; Maia, LN; Nicolau, JC; Santos, M; Vítola, JV, 2003)
"A total of 754 hypertensive patients with left ventricular hypertrophy (LVH) by Cornell voltage-duration product or Sokolow-Lyon voltage criteria on a screening electrocardiogram had their LV mass measured by echocardiogram at enrolment in the Losartan Intervention For Endpoint Reduction (LIFE) trial, and after 12 and 24 months of blinded therapy with losartan-based or atenolol-based regimens."5.10Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Liu, JE; Nieminen, MS; Palmieri, V; Papademetriou, V; Wachtell, K, 2002)
"To evaluate effectiveness of nonpeptide angiotensin-2 subtype-1 receptor antagonist losartan in therapy of symptomatic congestive heart failure in patients with ischemic heart disease, 116 patients were examined at the age of 36-62 (mean age 50."5.09[Losartan in therapy of chronic heart failure]. ( Berezin, AE; Vizir, VA, 2000)
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."4.21 ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)
"Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI)."3.91Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. ( Ahmad, M; Leenen, FHH; Llorens-Cortes, C; Marc, Y, 2019)
"Glucose metabolism, insulin, lipid, and ACE activity disorders observed with obesity were minimized by Losartan."3.80AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity. ( Campos, DH; Cicogna, AC; Fernandes, T; Guizoni, DM; Martinez, PF; Okoshi, K; Okoshi, MP; Oliveira, EM; Oliveira-Junior, SA; Padovani, CR, 2014)
"These findings show that although losartan and aliskiren exerted similar antihypertensive effects, only losartan prevented the activation of vascular profibrotic mechanisms and MMP upregulation associated with vascular remodeling in 2K1C hypertension."3.79Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling. ( Casarini, DE; Castro, MM; Ceron, CS; Costa-Neto, CM; Gerlach, RF; Guimaraes, D; Martins-Oliveira, A; Oliveira, DM; Reis, RI; Ribeiro, AA; Rizzi, E; Tanus-Santos, JE, 2013)
" We here examined the effects of QL on the development of cardiac hypertrophy through comparing those of losartan in C57BL/6 mice underlying transverse aorta constriction for 4 weeks."3.78Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice. ( Ge, J; Gong, H; Jia, Z; Li, L; Li, Y; Liang, Y; Lin, L; Wei, J; Wu, J; Wu, Y; Ye, Y; Zhou, J; Zhou, N; Zou, Y, 2012)
"Treatment with the selective VDR activator paricalcitol reduces myocardial fibrosis and preserves diastolic LV function due to pressure overload in a mouse model."3.78The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. ( Cannon, MV; de Boer, RA; Mahmud, H; Meems, LM; Ruifrok, WP; Silljé, HH; van Gilst, WH; Voors, AA, 2012)
"This study tested the reversal of subcellular remodelling in heart failure due to myocardial infarction (MI) upon treatment with losartan, an angiotensin II receptor antagonist."3.78Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction. ( Babick, A; Chapman, D; Dhalla, NS; Elimban, V; Zieroth, S, 2012)
"The purpose of this study was to evaluate the feasibility of noninvasive imaging of angiotensin II (AT) receptor upregulation in a mouse model of post-myocardial infarction (MI) heart failure (HF)."3.74Noninvasive imaging of angiotensin receptors after myocardial infarction. ( Bjurgert, E; Cuthbertson, A; Hofstra, L; Indrevoll, B; Kindberg, GM; Krasieva, TB; Lovhaug, D; Narula, J; Narula, N; Petersen, LB; Petrov, AD; Reutelingsperger, CP; Solbakken, M; Tromberg, BJ; Vannan, MA; Verjans, JW, 2008)
"The Ang II/Rac1/STAT3 pathway is an important signaling pathway in the atrial myocardium to mediate atrial structural remodeling, and losartan and statin may be able to reverse Ang II-induced atrial structural remodeling in atrial fibrillation."3.74Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. ( Chiang, FT; Hsieh, CS; Hsu, KL; Hwang, JJ; Kuo, KT; Lai, LP; Lin, JL; Tsai, CT; Tseng, CD; Tseng, YZ, 2008)
"Rats harboring the human renin and angiotensinogen genes (dTGR) feature angiotensin (ANG) II/hypertension-induced cardiac damage and die suddenly between wk 7 and 8."3.74Angiotensin II-induced sudden arrhythmic death and electrical remodeling. ( Dechend, R; Dietz, R; Fiebeler, A; Fischer, R; Gapelyuk, A; Gratze, P; Gruner, A; Gruner, K; Luft, FC; Muller, DN; Qadri, F; Schirdewan, A; Shagdarsuren, E; Wellner, M, 2007)
"To compare the effects of doxycycline, losartan, and their combination in the prevention of left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in rats."3.73[Comparison of doxycycline, losartan, and their combination in the prevention of post-infarction remodeling in rats]. ( Chen, X; Chen, ZJ; Gao, RL; Ruan, YM; Tian, Y; Yang, YJ; Zhang, P; Zhou, YW, 2005)
"Wistar rats were divided into the following 4 groups: 1) C--control (n=13); 2) AoS--aortic stenosis (n=11); 3) LIS--AoS treated with lisinopril, 20 mg/kg/day (n=11); and 4) LOS--AoS treated with losartan, 40 mg/kg/day (n=9)."3.73[Blockade of renin-angiotensin system attenuates cardiac remodeling in rats undergoing aortic stenosis]. ( Aragon, FF; Cicogna, AC; Cordaro, FR; Gonçalves, G; Okoshi, K; Okoshi, MP; Padovani, CR; Ribeiro, HB; Zornoff, LA, 2005)
"This study was carried out to investigate the effects of early administration of losartan on ventricular remodelling (VR) in rabbits with experimental myocardial infarction (MI)."3.72[Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction]. ( Depetris Chauvin, A; Gelpi, RJ; González, GE; Mangas, F; Morales, C; Palleiro, J; Rodríguez, M, 2004)
"We investigated in Lewis normotensive rats the effect of coronary artery ligation on the expression of cardiac angiotensin-converting enzymes (ACE and ACE 2) and angiotensin II type-1 receptors (AT1a-R) 28 days after myocardial infarction."3.72Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. ( Averill, DB; Brosnihan, KB; Ferrario, CM; Gallagher, PE; Ishiyama, Y; Tallant, EA, 2004)
"It has been verified that losartan has beneficial effects on ventricular remodeling (VRM) after acute myocardial infarction (AMI), but the effects of carvedilol alone or in combination with losartan on this condition have not been defined."3.72Comparative effects of carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats. ( Chen, JL; Chen, ZJ; Gao, RL; Ruan, YM; Tang, YD; Wang, PH; Yang, YJ; Zhang, P; Zhou, YW, 2003)
"To compare the effects of carvedilol, losartan and their combination in preventing from left ventricular remodeling (LVRM) after acute myocardial infarction(AMI) in rats."3.71[Comparative effects of carvedilol, losartan and their combination in preventing left ventricular remodeling after acute myocardial infarction in rats]. ( Chen, Z; Gao, R; Li, Y; Ruan, Y; Tang, Y; Yang, Y, 2001)
"To compare the effects of losartan, enalapril and their combination in the prevention of left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in the rat."3.71Comparison of the effects of losartan, enalapril and their combination in the prevention of left ventricular remodeling after acute myocardial infarction in the rat. ( Laifeng, S; Pei, Z; Xinglin, X; Yanwen, Z; Yi, T; Yingmao, R; Yishu, X; Yongli, L; Yuejin, Y; Zaijia, C, 2002)
"To investigate effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in the spontaneously hypertensive rats (SHR)."3.71[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats]. ( He, BX; Liang, XQ; Yu, GL, 2001)
"The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure."3.71Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. ( Ellingsen, O; Falck, G; Loennechen, JP; Wisløff, U, 2002)
" The use of losartan myocardial infarction causes an attenuation of ventricular remodeling, bringing about an increased survival, an attenuation of ventricular hypertrophy and dilation, and an improvement of the isovolumetric pressure; 2."3.70Effects of losartan on ventricular remodeling in experimental infarction in rats. ( Matsubara, BB; Matsubara, LS; Paiva, SA; Spadaro, J; Zornoff, LA, 2000)
"To determine the effects of losartan and captopril treatment on ventricular remodeling and function after myocardial infarction in rats."3.70Comparative effects of losartan and captopril on ventricular remodeling and function after myocardial infarction in the rat. ( Chen, H; Pan, W; Pu, S; Shen, X; Yang, Y; Zhang, G, 1998)
"Treatment with losartan had no effect on cardiac function or exercise capacity compared with placebo."2.82Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial. ( Axelsson, A; Bundgaard, H; Havndrup, O; Ho, CY; Iversen, K; Jensen, M; Kofoed, KF; Norsk, J; Vejlstrup, N, 2016)
"We examined the effect of losartan on ventricular remodeling after AMI comparatively with that of enalapril."2.71Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction. ( Hanada, H; Higuma, T; Ishizaka, H; Maeda, N; Matsunaga, T; Mori, Y; Okumura, K; Onodera, H; Osanai, T; Sasaki, S; Tamura, Y; Yoshimachi, F, 2005)
"Obesity has been shown to be associated with increased left ventricular mass (LVM) and heart sympathetic activity even in nonhypertensive subjects."2.71Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial. ( Amador, N; Encarnación, JJ; Guízar, JM; López, M; Rodríguez, L, 2005)
"Losartan treatment prevented tumor-induced loss of muscle mass and in vitro c26 cell proliferation, decreased tumor weight, and attenuated myocardial expression of interleukin-6."1.42Losartan treatment attenuates tumor-induced myocardial dysfunction. ( Bicer, S; Clark, Y; Devine, RD; Jing, R; McCarthy, DO; Reiser, PJ; Stevens, SC; Velten, M; Wold, LE; Youtz, DJ, 2015)
"Treatment with losartan reduced left ventricular dysfunction and prevented increased extracellular volume fraction, indicating that T1 mapping is sensitive to pharmacological prevention of fibrosis."1.40T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy. ( Fiedler, LR; Gsell, W; Habib, J; McSweeney, SJ; Prasad, SK; Price, AN; Schneider, MD; Stuckey, DJ; Thin, MZ, 2014)
"Losartan treatment significantly decreased MAP, left ventricle hypertrophy (LVH), fibrosis, and increased cardiac ACE2 and Mas expression."1.40Alteration of cardiac ACE2/Mas expression and cardiac remodelling in rats with aortic constriction. ( Li, B; Morgan, T; Wang, B; Wu, J; Zhang, J; Zhang, Y, 2014)
"Losartan was administered to individually caged rats via the drinking water (10 mg/kg/d)."1.38Cardiac remodeling and function following exercise and angiotensin II receptor antagonism. ( Libonati, JR, 2012)
"Metoprolol treatment for 2 weeks improved LV systolic function."1.35Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction. ( Kerkelä, R; Kubin, AM; Leskinen, H; Pieviläinen, O; Ruskoaho, H; Serpi, R; Soini, Y; Tenhunen, O; Tolonen, AM; Vaskivuo, T, 2009)
" These results indicate that effects on cardiac load by peripheral AT(1) receptor blockade or the pharmacokinetic profile of subcutaneous versus oral dosing do not contribute to the different cardiac effects of central versus systemic AT(1) receptor blockade post-MI."1.35Chronic central versus systemic blockade of AT(1) receptors and cardiac dysfunction in rats post-myocardial infarction. ( Ahmad, M; Huang, BS; Leenen, FH; Tan, J, 2009)
"Losartan treatment and exercise training were initiated 1 week after infarction and continued for 8 weeks, either as a single intervention or combined."1.35Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats. ( Erikson, JM; Ji, L; Lao, S; Powers, AS; Wan, W; Xu, X; Zhang, JQ; Zhao, W, 2008)
"To determine whether AII can induce cardiac hypertrophy directly via myocardial AT1R in the absence of vascular changes, transgenic mice overexpressing the human AT1R under the control of the mouse alpha-myosin heavy chain promoter were generated."1.31Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. ( Dali-Youcef, N; Nemer, M; Paradis, FW; Paradis, P; Thibault, G, 2000)
"Treatment with losartan (10 mg/kg/day) began 1 week post-MI and moderate treadmill exercise (25 m/min, 60 min/day, 5 days/week) was initiated 2 weeks post-MI."1.31Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodelling in rats. ( Apstein, CS; Eberli, FR; Jain, M; Liao, R; Ngoy, S; Whittaker, P, 2000)

Research

Studies (79)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (2.53)18.2507
2000's50 (63.29)29.6817
2010's23 (29.11)24.3611
2020's4 (5.06)2.80

Authors

AuthorsStudies
Nese, M1
Riboli, G1
Brighetti, G1
Sassi, V1
Camela, E1
Caselli, G1
Sassaroli, S1
Borlimi, R1
Aucoin, M1
Cooley, K1
Saunders, PR1
Carè, J1
Anheyer, D1
Medina, DN1
Cardozo, V1
Remy, D1
Hannan, N1
Garber, A1
Velayos, M1
Muñoz-Serrano, AJ1
Estefanía-Fernández, K1
Sarmiento Caldas, MC1
Moratilla Lapeña, L1
López-Santamaría, M1
López-Gutiérrez, JC1
Li, J2
Zhang, J2
Shen, S1
Zhang, B2
Yu, WW1
Toyoda, H1
Huang, DQ1
Le, MH1
Nguyen, MH1
Huang, R1
Zhu, L1
Wang, J7
Xue, L1
Liu, L3
Yan, X2
Huang, S1
Li, Y8
Xu, T1
Li, C2
Ji, F1
Ming, F1
Zhao, Y3
Cheng, J1
Wang, Y3
Zhao, H1
Hong, S1
Chen, K2
Zhao, XA1
Zou, L1
Sang, D1
Shao, H1
Guan, X1
Chen, X3
Chen, Y4
Wei, J2
Zhu, C1
Wu, C1
Moore, HB1
Barrett, CD1
Moore, EE1
Jhunjhunwala, R1
McIntyre, RC1
Moore, PK1
Hajizadeh, N1
Talmor, DS1
Sauaia, A1
Yaffe, MB1
Liu, C3
Lin, Y1
Dong, Y1
Wu, Y2
Bao, Y1
Yan, H2
Ma, J1
Fernández-Cuadros, ME1
Albaladejo-Florín, MJ1
Álava-Rabasa, S1
Usandizaga-Elio, I1
Martinez-Quintanilla Jimenez, D1
Peña-Lora, D1
Neira-Borrajo, I1
López-Muñoz, MJ1
Rodríguez-de-Cía, J1
Pérez-Moro, OS1
Abdallah, M1
Alsaleh, H1
Baradwan, A1
Alfawares, R1
Alobaid, A1
Rasheed, A1
Soliman, I1
Wendel Garcia, PD1
Fumeaux, T1
Guerci, P1
Heuberger, DM1
Montomoli, J2
Roche-Campo, F1
Schuepbach, RA1
Hilty, MP1
Poloni, TE1
Carlos, AF1
Cairati, M1
Cutaia, C1
Medici, V1
Marelli, E1
Ferrari, D1
Galli, A1
Bognetti, P1
Davin, A1
Cirrincione, A1
Ceretti, A1
Cereda, C1
Ceroni, M1
Tronconi, L1
Vitali, S1
Guaita, A1
Leeds, JS1
Raviprakash, V1
Jacques, T1
Scanlon, N1
Cundall, J1
Leeds, CM1
Riva, A1
Gray, EH1
Azarian, S1
Zamalloa, A1
McPhail, MJW1
Vincent, RP1
Williams, R1
Chokshi, S1
Patel, VC1
Edwards, LA1
Alqarawi, W1
Birnie, DH1
Golian, M1
Nair, GM1
Nery, PB1
Klein, A1
Davis, DR1
Sadek, MM1
Neilipovitz, D1
Johnson, CB1
Green, MS1
Redpath, C1
Miller, DC1
Beamer, P1
Billheimer, D1
Subbian, V1
Sorooshian, A1
Campbell, BS1
Mosier, JM1
Novaretti, JV1
Astur, DC1
Cavalcante, ELB1
Kaleka, CC1
Amaro, JT1
Cohen, M1
Huang, W1
Li, T1
Ling, Y1
Qian, ZP1
Zhang, YY1
Huang, D1
Xu, SB1
Liu, XH1
Xia, L1
Yang, Y5
Lu, SH1
Lu, HZ1
Zhang, R2
Ma, JX1
Tang, S1
Li, CM1
Wan, J1
Wang, JF1
Ma, JQ1
Luo, JJ1
Chen, HY2
Mi, SL1
Chen, SY1
Su, YG1
Ge, JB1
Milheiro, SA1
Gonçalves, J1
Lopes, RMRM1
Madureira, M1
Lobo, L1
Lopes, A1
Nogueira, F1
Fontinha, D1
Prudêncio, M1
M Piedade, MF1
Pinto, SN1
Florindo, PR1
Moreira, R1
Castillo-Lora, J1
Delley, MF1
Laga, SM1
Mayer, JM1
Sutjarit, N1
Thongon, N1
Weerachayaphorn, J1
Piyachaturawat, P1
Suksamrarn, A1
Suksen, K1
Papachristou, DJ1
Blair, HC1
Hu, Y1
Shen, P1
Zeng, N1
Wang, L3
Yan, D1
Cui, L1
Yang, K2
Zhai, C1
Yang, M1
Lao, X1
Sun, J1
Ma, N1
Wang, S1
Ye, W1
Guo, P1
Rahimi, S1
Singh, MP1
Gupta, J1
Nakanishi, I1
Ohkubo, K1
Shoji, Y1
Fujitaka, Y1
Shimoda, K1
Matsumoto, KI1
Fukuhara, K1
Hamada, H1
van der Boom, T1
Gruppen, EG1
Lefrandt, JD1
Connelly, MA1
Links, TP1
Dullaart, RPF1
Berry, JD1
Bedlack, R1
Mathews, D1
Agnese, W1
Apple, S1
Meloncelli, S1
Divizia, M1
Germani, G1
Adefegha, SA1
Bottari, NB1
Leal, DB1
de Andrade, CM1
Schetinger, MR1
Martínez-Velasco, A1
Perez-Ortiz, AC1
Antonio-Aguirre, B1
Martínez-Villaseñor, L1
Lira-Romero, E1
Palacio-Pastrana, C1
Zenteno, JC1
Ramirez, I1
Zepeda-Palacio, C1
Mendoza-Velásquez, C1
Camacho-Ordóñez, A1
Ortiz Bibriesca, DM1
Estrada-Mena, FJ1
Martin, BL1
Thompson, LC1
Kim, YH2
Snow, SJ1
Schladweiler, MC1
Phillips, P1
Harmon, M1
King, C1
Richards, J1
George, I1
Haykal-Coates, N1
Gilmour, MI1
Kodavanti, UP1
Hazari, MS1
Farraj, AK1
Shen, Z1
Zou, Y2
Gao, K1
Lazar, S1
Wurtzel, JGT1
Ma, P1
Goldfinger, LE1
Vukelic, M1
Laloo, A1
Kyttaris, VC1
Chen, R1
Chen, J2
Xun, J1
Hu, Z1
Huang, Q2
Steinhart, C1
Shen, Y1
Lu, H1
Mansuri, A1
Lokhande, K1
Kore, S1
Gaikwad, S1
Nawani, N1
Swamy, KV1
Junnarkar, M1
Pawar, S1
Shaheen, MY1
Basudan, AM1
Niazy, AA1
van den Beucken, JJJP1
Jansen, JA1
Alghamdi, HS1
Gao, Q2
Guo, X2
Cao, Y1
Jia, X1
Xu, S1
Lu, C2
Zhu, H3
Melku, M1
Abebe, G1
Teketel, A1
Asrie, F1
Yalew, A1
Biadgo, B1
Kassa, E1
Damtie, D1
Anlay, DZ1
Ahmed, MFE1
Ramadan, H1
Seinige, D1
Kehrenberg, C1
Abd El-Wahab, A1
Volkmann, N1
Kemper, N1
Schulz, J1
Hu, MY1
Wu, YN1
McEvoy, MP1
Wang, YF1
Cong, WL1
Liu, LP1
Li, XX1
Zhou, CL1
Chen, WM1
Wei, KL1
Tung, SY1
Shen, CH1
Chang, TS1
Yen, CW1
Hsieh, YY1
Chiu, WN1
Hu, JH1
Lu, SN1
Hung, CH1
Alakavuklar, MA1
Fuqua, C1
Luo, KL1
Underwood, RS1
Greenwald, I1
Elashiry, MM1
Elashiry, M1
Zeitoun, R1
Elsayed, R1
Tian, F1
Saber, SE1
Elashry, SH1
Tay, FR1
Cutler, CW1
O'Dowd, A1
Maciel, M1
Poole, ST1
Jobling, MG1
Rollenhagen, JE1
Woods, CM1
Sincock, SA1
McVeigh, AL1
Gregory, MJ1
Maves, RC1
Prouty, MG1
Holmes, RK1
Savarino, SJ1
Mor, MK1
Palevsky, PM1
Kaufman, JS1
Thiessen Philbrook, H1
Weisbord, SD1
Parikh, CR1
John, CM1
Phillips, NJ1
Jarvis, GA1
Zhu, Y1
Kilburn, S1
Kapoor, M1
Chaturvedi, S1
Shaw, KJ1
Chaturvedi, V1
Kong, X1
Zhang, T1
Xiao, H1
Feng, X1
Tu, H1
Feng, J1
Sabet, M1
Tarazi, Z1
Griffith, DC1
Nguyen, F1
Guan, P1
Guerrero, DT1
Kolla, V1
Naraparaju, K1
Perry, LM1
Soberman, D1
Pressly, BB1
Alferiev, IS1
Chorny, M1
Brodeur, GM1
Gao, X2
Cheng, YH1
Enten, GA1
DeSantis, AJ1
Gaponenko, V1
Majetschak, M1
Kim, DY1
Choi, MJ1
Ko, TK1
Lee, NH1
Kim, OH1
Cheon, HG1
Cai, H2
Yip, V1
Lee, MV1
Wong, S1
Saad, O1
Ma, S1
Ljumanovic, N1
Khojasteh, SC1
Kamath, AV1
Shen, BQ1
Cuypers, ML1
Chanteux, H1
Gillent, E1
Bonnaillie, P1
Saunders, K1
Beckers, C1
Delatour, C1
Dell'Aiera, S1
Ungell, AL1
Nicolaï, J1
Knapp, AK1
Chen, A1
Griffin-Nolan, RJ1
Baur, LE1
Carroll, CJW1
Gray, JE1
Hoffman, AM1
Li, X4
Post, AK1
Slette, IJ1
Collins, SL1
Luo, Y1
Smith, MD1
Temitayo, GI1
Olawande, B1
Emmanuel, YO1
Timothy, AT1
Kehinde, O1
Susan, LF1
Ezra, L1
Joseph, OO1
Lev, S1
Desmarini, D1
Liuwantara, D1
Sorrell, TC1
Hawthorne, WJ1
Djordjevic, JT1
Verso, MG1
Costantino, C1
Marrella, A1
Immordino, P1
Vitale, F1
Amodio, E1
Wang, YD1
Yao, WL1
Xin, ZM1
Han, TT1
Wang, ZG1
Chen, L1
Cai, C1
Zhang, Y6
Ba, D1
Wen, S1
Tian, Q1
Lv, W1
Cheng, G1
Li, N1
Yue, XY1
Chu, WJ1
Chen, Q1
Choi, ES1
Zhao, X3
Zhou, HD1
Sun, XF1
Sharma, S2
Chhoker, S1
Xie, C1
Ong, EWY1
Tan, ZK1
Evans, S1
Weinheimer, CJ1
Kovacs, A1
Williams, JW1
Randolph, GJ1
Jiang, W1
Barger, PM1
Mann, DL2
Liu, J2
Huang, Y1
Kong, L1
Yu, X1
Feng, B1
Liu, D1
Zhao, B1
Mendes, GC1
Yuan, P1
Ge, D1
Wang, WM1
Fontes, EPB1
Li, P2
Shan, L1
He, P1
Katoh, T1
Sengoku, T1
Hirata, K1
Ogata, K1
Suga, H1
Shun, C1
Yong-Yi, J1
Mei-Li, C1
Shi-Li, L1
Jian-Bo, Z1
Dan-Li, W1
Zhi-Min, G1
Ibrahim, AM1
Zakhary, SY1
Amin, SAW1
Ugurlu, M1
Fornari, VJ1
Hartmann, MSM1
Vanni, JR1
Rodriguez, R1
Langaro, MC1
Pelepenko, LE1
Zaia, AA1
Nakanjako, D1
Zalwango, F1
Wairagala, P1
Luboga, F1
Andia Biraro, I1
Bukirwa, VD1
Mboowa, MG1
Cose, S1
Seeley, J1
Elliott, A1
Zhao, G1
Sun, P1
Hao, S1
Wang, X1
Qu, G1
Xing, Y1
Xu, X2
Maierhofer, M1
Rieger, V1
Mayr, T1
Liu, Y3
Zhang, Q1
Bigliardi, AP1
Fernandes, CLF1
Pinto, EA1
Dos Santos, M1
Garcia, EM1
Baisch, PRM1
Soares, MCF1
Muccillo-Baisch, AL1
da Silva Júnior, FMR1
Yu, W1
Ju, C1
Wang, K1
Zheng, Z1
Liu, H1
Gao, Y1
Martínez-Navarro, EM1
Cebrián-Tarancón, C1
Moratalla-López, N1
Lorenzo, C1
Alonso, GL1
Salinas, RM1
Bermúdez de Castro, JM1
Modesto-Mata, M1
Martín-Francés, L1
García-Campos, C1
Martínez de Pinillos, M1
Martinón-Torres, M1
Hasani, M1
Wu, F2
Warriner, K1
Kurz, M1
Gretzke, D1
Hörlein, R1
Turpault, S1
Atzrodt, J1
Derdau, V1
Yao, Y1
Ou, X1
Zhao, S1
Tian, B1
Jin, S1
Jiang, Z1
Zhou, Z1
Liu, M2
Jiang, GD1
Mou, LH1
Chen, JJ1
Li, ZY1
He, SG1
Reale, E1
Fustinoni, S1
Mercadante, R1
Polledri, E1
Hopf, NB1
Grant, PC1
Levy, K1
Lattimer, TA1
Depner, RM1
Kerr, CW1
Sato, J1
Merenda, MEZ1
Uemoto, AT1
Dos Santos, MP1
Barion, MRL1
Carciofi, AC1
de Paula Dorigam, JC1
Ribeiro, LB1
Vasconcellos, RS1
Waller, SB1
Peter, CM1
Hoffmann, JF1
Cleff, MB1
Faria de, RO1
Zani, JL1
Martins, BA1
Sande, D1
Solares, MD1
Takahashi, JA1
Yang, S2
Jia, Y1
Yin, C1
Zhao, R1
Ojha, M1
Wu, B1
Deepa, M1
Mo, J1
Au, DW1
Wan, MT1
Shi, J1
Zhang, G2
Winkler, C1
Kong, RY1
Seemann, F1
Bianco, M1
Calvano, CD1
Ventura, G1
Bianco, G1
Losito, I1
Cataldi, TRI1
Angiolella, L1
Staudt, A1
Duarte, PF1
Amaral, BPD1
Peixoto Andrade, BCO1
Simas, NK1
Correa Ramos Leal, I1
Sangenito, LS1
Santos, ALSD1
de Oliveira, D1
Junges, A1
Cansian, RL1
Paroul, N1
Siu, J1
Klingler, L1
Hung, CT1
Jeong, SH1
Smith, S2
Tingle, MD1
Wagner Mackenzie, B1
Biswas, K1
Douglas, RG1
Oza, AM1
Lorusso, D1
Aghajanian, C1
Oaknin, A1
Dean, A1
Colombo, N1
Weberpals, JI1
Clamp, AR1
Scambia, G1
Leary, A1
Holloway, RW1
Gancedo, MA1
Fong, PC1
Goh, JC1
O'Malley, DM1
Armstrong, DK1
Banerjee, S1
García-Donas, J1
Swisher, EM1
Cella, D1
Meunier, J1
Goble, S1
Cameron, T1
Maloney, L1
Mörk, AC1
Bedel, J1
Ledermann, JA1
Coleman, RL1
Vlek, SL1
Burm, R1
Govers, TM1
Vleugels, MPH1
Tuynman, JB1
Mijatovic, V1
Leicht, AS1
Connor, J1
Conduit, N1
Vaquera, A1
Gómez, MA1
McKay, JA1
Church, AL1
Rubin, N1
Emory, TH1
Hoven, NF1
Kuehn-Hajder, JE1
Nelson, MT1
Ramanna, S1
Auerbach, EJ1
Moeller, S1
Bolan, PJ1
Fox, NP1
Leonard, M1
Sjerps, MJ1
Chang, EF1
Hyun, S1
Saejio, A1
Shanmugam, S1
Liu, X2
Sun, M2
Bai, Z1
Jaque-Fernandez, F1
Beaulant, A1
Berthier, C1
Monteiro, L1
Allard, B1
Casas, M1
Rieusset, J1
Jacquemond, V1
Góngora-García, OR1
Aca-Aca, G1
Baz-Rodríguez, SA1
Monte, A1
Maganaris, C1
Baltzopoulos, V1
Zamparo, P1
Wang, Z2
Hou, Y1
Cai, L1
Tu, YJ1
Tan, B1
Jiang, L1
Wu, ZH1
Yu, HJ1
Li, XQ1
Yang, AD1
Titze, IR1
Palaparthi, A1
Mau, T1
González, MA1
Goiri, F1
Barandika, JF1
García-Pérez, AL1
Jatt, LP1
Gandhi, MM1
Guo, R1
Sukhija-Cohen, A1
Bhattacharya, D1
Tseng, CH1
Chew, KW1
Onwumere, J1
Pia Tek, J1
Budnyak, T1
Budnyk, S1
Karim, Z1
Thersleff, T1
Kuśtrowski, P1
Mathew, AP1
Slabon, A1
Guo, M1
Zhao, T1
Xing, Z1
Qiu, Y1
Pan, K1
Li, Z3
Zhou, W1
Ghassemi Tabrizi, S1
Arbuznikov, AV1
Jiménez-Hoyos, CA1
Kaupp, M1
Lin, MH2
Bulman, DM1
Remucal, CK1
Chaplin, BP1
Laguerre, A1
George, LA1
Gall, ET1
Emerson, MS1
Wang, H3
Maginn, EJ1
Margulis, CJ1
Li, H2
Feng, W1
Kang, X2
Yan, S1
Chao, M1
Mo, S1
Sun, W1
Lu, Y1
Chen, C1
Stevens, DM1
Adiseshaiah, P1
Dasa, SSK1
Potter, TM1
Skoczen, SL1
Snapp, KS1
Cedrone, E1
Patel, N1
Busman-Sahay, K1
Rosen, EP1
Sykes, C1
Cottrell, M1
Dobrovolskaia, MA1
Estes, JD1
Kashuba, ADM1
Stern, ST1
Özütemiz, C1
Neil, EC1
Tanwar, M1
Rubin, NT1
Ozturk, K1
Cayci, Z1
Duscha, BD1
Kraus, WE1
Jones, WS1
Robbins, JL1
Piner, LW1
Huffman, KM1
Allen, JD1
Annex, BH1
Mehmood, T1
Ahmad, I1
Bibi, S1
Mustafa, B1
Ali, I1
Dahal, RH1
Chaudhary, DK1
Kim, DU1
Kim, J2
Yeter, HH1
Gonul, I1
Guz, G1
Helvaci, O1
Korucu, B1
Akcay, OF1
Derici, U1
Arinsoy, T1
Neffati, R1
Judeinstein, P1
Rault, J1
Xu, Y1
Chai, X1
Ren, T1
Yu, S1
Fu, Q2
Ye, J1
Ge, X1
Song, J1
Yang, H2
El-Baba, TJ1
Lutomski, CA1
Kantsadi, AL1
Malla, TR1
John, T1
Mikhailov, V1
Bolla, JR1
Schofield, CJ1
Zitzmann, N1
Vakonakis, I1
Robinson, CV1
Langham, MC1
Caporale, AS1
Wehrli, FW1
Parry, S1
Schwartz, N1
den Boer, RB1
Jones, KI1
Ash, S1
van Boxel, GI1
Gillies, RS1
O'Donnell, T1
Ruurda, JP1
Sgromo, B1
Silva, MA1
Maynard, ND1
Sivieri, EM1
Eichenwald, EC1
Rub, D1
Abbasi, S1
Krahnert, I1
Bolze, A1
Gibon, Y1
Fernie, AR1
Huang, L1
Wan, Y1
Dang, Z1
Yang, P1
Yang, Q1
Wu, S2
Lin, CC1
Hsu, CT1
Liu, W2
Huang, SC1
Kortz, U1
Mougharbel, AS1
Chen, TY1
Hu, CW1
Lee, JF1
Wang, CC1
Liao, YF1
Li, LJ1
Li, L3
Peng, S1
Stimming, U1
Hebbar Kannur, K1
Yaqub, TB1
Pupier, C1
Héau, C1
Cavaleiro, A1
Yamamoto, S1
Ono, A1
Matsui, J1
Hoshino, N1
Akutagawa, T1
Miyashita, T1
Mitsuishi, M1
Patel, SM1
Smith, TG1
Morton, M1
Stiers, KM1
Seravalli, J1
Mayclin, SJ1
Edwards, TE1
Tanner, JJ1
Becker, DF1
Butcher, TW1
Yang, JL1
Hartwig, JF1
Yu, MF1
Xia, ZZ1
Yao, JC1
Feng, Z1
Li, DH1
Liu, T1
Cheng, GJ1
He, DL1
Li, XH1
Huurman, R1
Schinkel, AFL1
de Jong, PL1
van Slegtenhorst, MA1
Hirsch, A1
Michels, M1
Kataja, A1
Tarvasmäki, T1
Lassus, J1
Sionis, A1
Mebazaa, A1
Pulkki, K1
Banaszewski, M1
Carubelli, V1
Hongisto, M1
Jankowska, E1
Jurkko, R1
Jäntti, T1
Kasztura, M1
Parissis, J1
Sabell, T1
Silva-Cardoso, J1
Spinar, J1
Tolppanen, H1
Harjola, VP1
Carsetti, A1
Damiani, E1
Casarotta, E1
Scorcella, C1
Domizi, R1
Gasparri, F1
Gabbanelli, V1
Pantanetti, S1
Carozza, R1
Adrario, E1
Donati, A1
Almada, E1
Pariani, A1
Rivabella Maknis, T1
Hidalgo, F1
Vena, R1
Favre, C1
Larocca, MC1
Lu, ZY1
Jiang, WD1
Wu, P1
Kuang, SY1
Tang, L1
Yang, J1
Zhou, XQ1
Feng, L1
Leal, M1
Zampini, IC1
Mercado, MI1
Moreno, MA1
Simirgiotis, MJ1
Bórquez, J1
Ponessa, G1
Isla, MI1
Saliu, IO1
Amoo, ZA1
Khan, MF1
Olaleye, MT1
Rema, V1
Akinmoladun, AC1
Khan, AU1
Rahman, AU1
Yuan, Q1
Ahmad, A1
Khan, ZUH1
Mahnashi, MH1
Alyami, BA1
Alqahtani, YS1
Ullah, S1
Wirman, AP1
Gao, M1
Deng, L2
Zhang, K1
Wang, M1
Xia, Z1
Gao, D1
Balkissou, AD1
Poka-Mayap, V1
Massongo, M1
Djenabou, A1
Endale-Mangamba, LM1
Olomo, EJ1
Boulleys-Nana, JR1
Diffo-Sonkoue, L1
Adidigue-Ndiome, R1
Alexandra, AJE1
Haman-Wabi, AB1
Adama, S1
Iddi-Faical, A1
Pefura-Yone, EW1
Zhao, Q1
Tong, W1
Ge, C1
Zhao, D1
Norbäck, D1
Li, B2
Zhao, Z1
Huang, C1
Zhang, X1
Qian, H1
Yang, X1
Sun, Y2
Sundell, J1
Deng, Q1
Kim, HJ1
Jeon, JW1
Hwang, SM1
Chu, KI1
Cha, YH1
Kwak, YD1
Choi, SD1
Aslam, M1
Kim, CG1
Zhou, J2
Yang, E1
Yang, W1
Gonzalez, EA1
Tobar Leitão, SA1
Soares, DDS1
Tavares, AMV1
Giugliani, R1
Baldo, G1
Matte, U1
Fried, ND1
Morris, TM1
Whitehead, A1
Lazartigues, E1
Yue, X1
Gardner, JD1
Wang, EY1
Kuzmanov, U1
Smith, JB1
Dou, W1
Rafatian, N1
Lai, BFL1
Lu, RXZ1
Wu, Q1
Yazbeck, J1
Zhang, XO1
Gramolini, A1
Radisic, M1
Bartko, PE1
Dal-Bianco, JP1
Guerrero, JL1
Beaudoin, J1
Szymanski, C1
Kim, DH1
Seybolt, MM1
Handschumacher, MD1
Sullivan, S1
Garcia, ML1
Titus, JS1
Wylie-Sears, J1
Irvin, WS1
Messas, E1
Hagège, AA1
Carpentier, A1
Aikawa, E1
Bischoff, J1
Levine, RA1
Zheng, M1
Pan, F1
Zhou, X1
Meng, X1
Ge, S1
Bertoluci, C2
Foppa, M2
Santos, ABS2
Branchi, TV1
Fuchs, SC2
Fuchs, FD2
Chen, P1
Qiao, D1
Leenen, FHH1
Ahmad, M2
Marc, Y1
Llorens-Cortes, C1
Oliveira-Junior, SA2
Dal Pai, M1
Guizoni, DM2
Torres, BP1
Martinez, PF2
Campos, DHS1
Okoshi, MP3
Okoshi, K3
Padovani, CR3
Cicogna, AC3
Friedberg, MK1
Cho, MY1
Assad, RS1
Rohailla, S1
Honjo, O1
Apitz, C1
Redington, AN1
Stuckey, DJ1
McSweeney, SJ1
Thin, MZ1
Habib, J1
Price, AN1
Fiedler, LR1
Gsell, W1
Prasad, SK1
Schneider, MD1
Campos, DH1
Fernandes, T1
Oliveira, EM2
Norris, AW1
Bahr, TM1
Scholz, TD1
Peterson, ES1
Volk, KA1
Segar, JL1
Wang, B1
Wu, J2
Morgan, T1
Stevens, SC1
Velten, M1
Youtz, DJ1
Clark, Y1
Jing, R1
Reiser, PJ1
Bicer, S1
Devine, RD1
McCarthy, DO1
Wold, LE1
Kelloniemi, A1
Aro, J2
Näpänkangas, J1
Koivisto, E1
Mustonen, E2
Ruskoaho, H3
Rysä, J2
Axelsson, A1
Iversen, K1
Vejlstrup, N1
Ho, CY1
Havndrup, O1
Kofoed, KF1
Norsk, J1
Jensen, M1
Bundgaard, H1
Maczewski, M1
Maczewska, J1
Duda, M1
Matsuhisa, S1
Otani, H1
Okazaki, T1
Yamashita, K1
Akita, Y1
Sato, D1
Moriguchi, A1
Iwasaka, T1
Liu, RY1
Zhao, XY1
Zhang, JY1
Jia, M1
Lu, PQ1
Verjans, JW1
Lovhaug, D2
Narula, N2
Petrov, AD1
Indrevoll, B1
Bjurgert, E1
Krasieva, TB1
Petersen, LB1
Kindberg, GM1
Solbakken, M1
Cuthbertson, A1
Vannan, MA2
Reutelingsperger, CP1
Tromberg, BJ1
Hofstra, L2
Narula, J2
van den Borne, SW1
Isobe, S1
Zandbergen, HR1
Petrov, A1
Wong, ND1
Fujimoto, S1
Fujimoto, A1
Smits, JF1
Daemen, MJ1
Blankesteijn, WM1
Reutelingsperger, C1
Zannad, F1
Pitt, B1
Mitsuhashi, H1
Tamura, K1
Yamauchi, J1
Ozawa, M1
Yanagi, M1
Dejima, T1
Wakui, H1
Masuda, S1
Azuma, K1
Kanaoka, T1
Ohsawa, M1
Maeda, A1
Tsurumi-Ikeya, Y1
Okano, Y1
Ishigami, T1
Toya, Y1
Tokita, Y1
Ohnishi, T1
Umemura, S1
González, GE2
Seropian, IM1
Krieger, ML1
Palleiro, J2
Lopez Verrilli, MA1
Gironacci, MM1
Cavallero, S1
Wilensky, L1
Tomasi, VH1
Gelpi, RJ2
Morales, C2
Tani, S1
Nagao, K1
Anazawa, T1
Kawamata, H1
Furuya, S1
Takahashi, H1
Iida, K1
Matsumoto, M1
Kumabe, N1
Onikura, M1
Hirayama, A1
Huang, BS1
Tan, J1
Leenen, FH1
Säkkinen, H1
Tokola, H1
Isopoussu, E1
Leskinen, H2
Serpi, R1
Tolonen, AM1
Tenhunen, O1
Pieviläinen, O1
Kubin, AM1
Vaskivuo, T1
Soini, Y1
Kerkelä, R1
McLaughlin, D1
Robinson, E1
Harvey, AP1
Hookham, MB1
Shah, AM1
McDermott, BJ1
Grieve, DJ1
Lymperopoulos, A1
Rengo, G1
Zincarelli, C1
Koch, WJ1
Lin, L1
Ye, Y1
Zhou, N1
Liang, Y1
Gong, H1
Jia, Z1
Ge, J1
Libonati, JR1
Martins-Oliveira, A1
Castro, MM1
Oliveira, DM1
Rizzi, E1
Ceron, CS1
Guimaraes, D1
Reis, RI1
Costa-Neto, CM1
Casarini, DE1
Ribeiro, AA1
Gerlach, RF1
Tanus-Santos, JE1
Meems, LM1
Cannon, MV1
Mahmud, H1
Voors, AA1
van Gilst, WH1
Silljé, HH1
Ruifrok, WP1
de Boer, RA1
Babick, A1
Chapman, D1
Zieroth, S1
Elimban, V2
Dhalla, NS2
Devereux, RB2
Palmieri, V1
Liu, JE1
Wachtell, K2
Bella, JN1
Boman, K2
Gerdts, E2
Nieminen, MS2
Papademetriou, V2
Dahlöf, B2
El-Adawi, H1
Tramontano, A1
Mascareno, E1
Ganguly, K1
Castillo, R1
El-Sherif, N1
Yu, GL2
Liang, XQ2
Zheng, JQ1
He, BX1
Patten, RD2
Aronovitz, MJ1
Einstein, M1
Lambert, M1
Pandian, NG1
Mendelsohn, ME1
Konstam, MA2
Yang, YJ2
Tang, YD1
Ruan, YM2
Zhang, P2
Zhou, YW2
Wang, PH1
Gao, RL2
Chen, JL1
Chen, ZJ2
Nicolau, JC2
Maia, LN2
Vítola, J1
Vaz, VD1
Machado, MN1
Godoy, MF1
Giraldez, RR1
Ramires, JA1
Vítola, JV1
Santos, M1
Brandi, JM1
Joaquim, MR1
Baggi, JM1
Cordeiro, JA1
de Godoy, MF1
Kim, YK1
Mankad, S3
Kim, SJ1
Takagi, G1
Tamura, T1
Gerdes, AM1
Bishop, SP1
Kramer, CM3
Flesch, M1
Höper, A1
Dell'Italia, L1
Evans, K1
Bond, R1
Peshock, R1
Diwan, A1
Brinsa, TA1
Wei, CC1
Sivasubramanian, N1
Spinale, FG1
Yuejin, Y1
Pei, Z1
Yingmao, R1
Laifeng, S1
Xinglin, X1
Yongli, L1
Yanwen, Z1
Yi, T1
Yishu, X1
Zaijia, C1
Umemoto, S1
Kawahara, S1
Hashimoto, R1
Matsuzaki, M1
Ishiyama, Y1
Gallagher, PE1
Averill, DB1
Tallant, EA1
Brosnihan, KB1
Ferrario, CM1
Mangas, F1
Rodríguez, M1
Depetris Chauvin, A1
Pourdjabbar, A2
Parker, TG2
Nguyen, QT2
Desjardins, JF2
Lapointe, N2
Tsoporis, JN2
Rouleau, JL2
Rokkedal, J1
Harris, K1
Aurup, P1
Amador, N1
Encarnación, JJ1
Guízar, JM1
Rodríguez, L1
López, M1
Epifanio, HB1
Zornoff, LA3
Matsubara, BB2
de Paiva, SA1
Inoue, RM1
Matsubara, LS2
Liu, YH1
Zeng, QT1
Chen, B1
Gonçalves, G1
Ribeiro, HB1
Cordaro, FR1
Aragon, FF1
Tian, Y1
Tang, Y1
Ruan, Y1
Gao, R1
Chen, Z1
Onodera, H1
Matsunaga, T1
Tamura, Y1
Maeda, N1
Higuma, T1
Sasaki, S1
Mori, Y1
Yoshimachi, F1
Ishizaka, H1
Hanada, H1
Osanai, T1
Okumura, K1
Xu, R1
Zhang, M1
Li, XC1
Chen, WQ1
Ge, ZM1
Zhang, W1
Fischer, R1
Dechend, R1
Gapelyuk, A1
Shagdarsuren, E1
Gruner, K1
Gruner, A1
Gratze, P1
Qadri, F1
Wellner, M1
Fiebeler, A1
Dietz, R1
Luft, FC1
Muller, DN1
Schirdewan, A1
Rocha, FL1
Carmo, EC1
Roque, FR1
Hashimoto, NY1
Rossoni, LV1
Frimm, C1
Anéas, I1
Negrão, CE1
Krieger, JE1
Orn, S1
Manhenke, C1
Squire, IB1
Ng, L1
Anand, I1
Dickstein, K1
Tsai, CT1
Lai, LP1
Kuo, KT1
Hwang, JJ1
Hsieh, CS1
Hsu, KL1
Tseng, CD1
Tseng, YZ1
Chiang, FT1
Lin, JL1
Wan, W1
Ji, L1
Lao, S1
Powers, AS1
Zhao, W1
Erikson, JM1
Zhang, JQ1
Hongo, M1
Sentianin, EM1
Tanaka, N1
Mao, L1
McKirnan, MD1
Clark, RG1
Won, W1
Chien, KR1
Ross, J1
Paradis, P1
Dali-Youcef, N1
Paradis, FW1
Thibault, G1
Nemer, M1
Vizir, VA1
Berezin, AE1
Jain, M1
Liao, R1
Ngoy, S1
Whittaker, P1
Apstein, CS1
Eberli, FR1
Thomas, I1
Ramahi, T1
La Bresh, K1
Goldman, S1
Lewis, W1
Gradman, A1
Self, KS1
Bittner, V1
Rand, W1
Kinan, D1
Smith, JJ1
Ford, T1
Segal, R1
Udelson, JE1
Paiva, SA1
Spadaro, J1
Lee, S1
Yoo, SE1
Sandberg, K1
d'Amato, TA1
Reichek, N1
McGregor, WE1
Lin, J1
Singh, D1
Rogers, WJ1
Shen, X1
Pu, S1
Pan, W1
Chen, H1
Kiatchoosakun, S1
Lawrence, E1
Nakada, S1
Restivo, J1
Walsh, RA1
Hoit, BD1
Loennechen, JP1
Wisløff, U1
Falck, G1
Ellingsen, O1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
INHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan.[NCT01447654]Phase 2130 participants (Actual)Interventional2011-11-30Completed
A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798]Phase 2/Phase 344 participants (Actual)Interventional2014-05-31Terminated (stopped due to Futility)
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260]Phase 3496 participants (Actual)Interventional1995-06-30Completed
Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After ST-elevation Myocardial Infarction[NCT03516903]Phase 2/Phase 335 participants (Actual)Interventional2018-04-17Terminated (stopped due to Due to the COVID-19 pandemic. With a second wave just beginning, and considering that we are testing an immunosuppressant in patients with high risk for COVID-19 complications, we would not be able to re-start recruitment safely in the near future.)
The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019[NCT04338009]152 participants (Actual)Interventional2020-03-31Completed
Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI In Heart Failure: Implication on Early Remodeling and on the Transition to Heart Failure[NCT03084679]90 participants (Anticipated)Interventional2017-11-01Recruiting
Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321]100 participants (Anticipated)Observational2014-01-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All-Cause Death

(NCT04338009)
Timeframe: Up to 28 days

InterventionParticipants (Count of Participants)
Discontinuation Arm10
Continuation Arm11

AUC SOFA

"The Area Under the Curve of the modified SOFA (AUC SOFA) from daily measurements, weighted to account for the shorter observation period among patients who die in-hospital.~How to interpret the AUC SOFA?: a higher area indicates more severe disease and/or longer hospitalization.The range is 0.1 to 377.3." (NCT04338009)
Timeframe: Up to 28 days

Interventionunits on a scale (SOFA x days) (Median)
Discontinuation Arm7
Continuation Arm12

Hierarchical Composite Endpoint

"The primary endpoint of the trial will be a global rank based on patient outcomes according to four factors: (1) time to death, (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), (3) the number of days supported by renal replacement therapy or pressor/inotropic therapy, and (4) a modified sequential Organ Failure Assessment (SOFA) score. The modified SOFA score will include the cardiac, respiratory, renal and coagulation domains of the SOFA score.~How to interpret the rank?: patients are ranked from worst to best outcomes, such that patients with bad outcomes are ranked at the top and patients who have the best outcomes are ranked at the bottom." (NCT04338009)
Timeframe: Up to 28 days

Interventionscore on a scale (range 1 to 152) (Median)
Discontinuation Arm81
Continuation Arm73

Hypotension Requiring Vasopressors, Inotropes or Mechanical Hemodynamic Support

Hypotension Requiring Vasopressors, inotropes or mechanical hemodynamic support (ventricular assist device or intra-aortic balloon pump). (NCT04338009)
Timeframe: Up to 28 days

InterventionParticipants (Count of Participants)
Discontinuation Arm8
Continuation Arm9

Intensive Care Unit Admission or Respiratory Failure Requiring Mechanical Ventilation.

Need to be transferred to an intensive care unit or to supported by a breathing machine (NCT04338009)
Timeframe: Up to 28 days

InterventionParticipants (Count of Participants)
Discontinuation Arm14
Continuation Arm16

Length of Hospital Stay

This outcome measurement looked at the median length of hospitalization. (NCT04338009)
Timeframe: Up to 28 days

Interventiondays (Median)
Discontinuation Arm5
Continuation Arm6

Length of ICU Stay, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation

(NCT04338009)
Timeframe: Up to 28 days

Interventiondays (Median)
Discontinuation Arm15
Continuation Arm13

Reviews

2 reviews available for losartan and Cardiac Remodeling, Ventricular

ArticleYear
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
[Angiotensin receptor blockers in chronic heart failure].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9

    Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Fai

2003

Trials

14 trials available for losartan and Cardiac Remodeling, Ventricular

ArticleYear
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
Echocardiographic Left Ventricular Reverse Remodeling After 18 Months of Antihypertensive Treatment in Stage I Hypertension. Results From the Prever-Treatment Study.
    American journal of hypertension, 2018, 02-09, Volume: 31, Issue:3

    Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Atrial Function, Left; Atrial Remodeling; Blood Pre

2018
Diuretics are Similar to Losartan on Echocardiographic Target-Organ Damage in Stage I Hypertension. PREVER-Treatment Study.
    Arquivos brasileiros de cardiologia, 2019, Volume: 112, Issue:1

    Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Method; Ech

2019
Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial.
    Heart (British Cardiac Society), 2016, 02-15, Volume: 102, Issue:4

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Denmark; Disease

2016
Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis.
    Atherosclerosis, 2009, Volume: 207, Issue:1

    Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Ankle; Antihypertensive Agents; Biomarke

2009
Effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction: a possible mechanism of prevention of cardiac events by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk myocardial
    Internal medicine (Tokyo, Japan), 2009, Volume: 48, Issue:11

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Cardiotonic Agents;

2009
Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
    Journal of hypertension, 2002, Volume: 20, Issue:7

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Disease Progression; Double-Blind

2002
Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction.
    American heart journal, 2003, Volume: 145, Issue:6

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Enalapril; Fe

2003
Prognostic significance of left ventricular mass change during treatment of hypertension.
    JAMA, 2004, Nov-17, Volume: 292, Issue:19

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph

2004
Prognostic significance of left ventricular mass change during treatment of hypertension.
    JAMA, 2004, Nov-17, Volume: 292, Issue:19

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph

2004
Prognostic significance of left ventricular mass change during treatment of hypertension.
    JAMA, 2004, Nov-17, Volume: 292, Issue:19

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph

2004
Prognostic significance of left ventricular mass change during treatment of hypertension.
    JAMA, 2004, Nov-17, Volume: 292, Issue:19

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph

2004
Prognostic significance of left ventricular mass change during treatment of hypertension.
    JAMA, 2004, Nov-17, Volume: 292, Issue:19

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph

2004
Prognostic significance of left ventricular mass change during treatment of hypertension.
    JAMA, 2004, Nov-17, Volume: 292, Issue:19

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph

2004
Prognostic significance of left ventricular mass change during treatment of hypertension.
    JAMA, 2004, Nov-17, Volume: 292, Issue:19

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph

2004
Prognostic significance of left ventricular mass change during treatment of hypertension.
    JAMA, 2004, Nov-17, Volume: 292, Issue:19

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph

2004
Prognostic significance of left ventricular mass change during treatment of hypertension.
    JAMA, 2004, Nov-17, Volume: 292, Issue:19

    Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph

2004
Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial.
    Journal of human hypertension, 2005, Volume: 19, Issue:4

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Body Mass Index; Diuretics; Double-Blind Method; Ech

2005
Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction.
    American heart journal, 2005, Volume: 150, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Female; Humans;

2005
Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function.
    Journal of cardiac failure, 2007, Volume: 13, Issue:10

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers;

2007
[Losartan in therapy of chronic heart failure].
    Klinicheskaia meditsina, 2000, Volume: 78, Issue:2

    Topics: Adult; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Diuretics; Drug Therapy, Combinatio

2000
Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy.
    American heart journal, 2000, Volume: 139, Issue:6

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Ag

2000

Other Studies

64 other studies available for losartan and Cardiac Remodeling, Ventricular

ArticleYear
Cardiac pathology in mucopolysaccharidosis I mice: Losartan modifies ERK1/2 activation during cardiac remodeling.
    Journal of inherited metabolic disease, 2021, Volume: 44, Issue:3

    Topics: Animals; Disease Models, Animal; Echocardiography; Female; Heart Diseases; Iduronidase; Losartan; Ma

2021
Angiotensin II type 1 receptor mediates pulmonary hypertension and right ventricular remodeling induced by inhaled nicotine.
    American journal of physiology. Heart and circulatory physiology, 2021, 04-01, Volume: 320, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Disease Models, Animal; E-Cigar

2021
An organ-on-a-chip model for pre-clinical drug evaluation in progressive non-genetic cardiomyopathy.
    Journal of molecular and cellular cardiology, 2021, Volume: 160

    Topics: Angiotensin II; Animals; Cardiomyopathies; Cardiotonic Agents; Cell Line; Cell Survival; Coculture T

2021
Effect of Losartan on Mitral Valve Changes After Myocardial Infarction.
    Journal of the American College of Cardiology, 2017, Sep-05, Volume: 70, Issue:10

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography, Three-Di

2017
Echocardiographic Strain Analysis for the Early Detection of Myocardial Structural Abnormality and Initiation of Drug Therapy in a Mouse Model of Dilated Cardiomyopathy.
    Ultrasound in medicine & biology, 2017, Volume: 43, Issue:12

    Topics: Animals; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Disease Models, Animal; Echocardiography;

2017
Effects and Mechanism of SO2 Inhalation on Rat Myocardial Collagen Fibers.
    Medical science monitor : international medical journal of experimental and clinical research, 2018, Mar-21, Volume: 24

    Topics: Angiotensin II; Animals; Blood Pressure; Body Weights and Measures; Collagen; Heart; Heart Ventricle

2018
Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction.
    Journal of cardiovascular pharmacology, 2019, Volume: 73, Issue:2

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin III; Animals; Brain; Dise

2019
Effects of AT1 receptor antagonism on interstitial and ultrastructural remodeling of heart in response to a hypercaloric diet.
    Physiological reports, 2019, Volume: 7, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Collagen; Diet, High-Fat; Losartan

2019
Adverse biventricular remodeling in isolated right ventricular hypertension is mediated by increased transforming growth factor-β1 signaling and is abrogated by angiotensin receptor blockade.
    American journal of respiratory cell and molecular biology, 2013, Volume: 49, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Connective Tissue Growth Factor; Endoth

2013
T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy.
    Circulation. Cardiovascular imaging, 2014, Volume: 7, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Contrast Media; Disease Models, Animal; Dose-Respo

2014
AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Blood Glucose; Class Ia Phosphatidyl

2014
Angiotensin II-induced cardiovascular load regulates cardiac remodeling and related gene expression in late-gestation fetal sheep.
    Pediatric research, 2014, Volume: 75, Issue:6

    Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascul

2014
Alteration of cardiac ACE2/Mas expression and cardiac remodelling in rats with aortic constriction.
    The Chinese journal of physiology, 2014, Dec-31, Volume: 57, Issue:6

    Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Abdominal

2014
Losartan treatment attenuates tumor-induced myocardial dysfunction.
    Journal of molecular and cellular cardiology, 2015, Volume: 85

    Topics: Adenocarcinoma; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling;

2015
TSC-22 up-regulates collagen 3a1 gene expression in the rat heart.
    BMC cardiovascular disorders, 2015, Oct-13, Volume: 15

    Topics: Animals; Antihypertensive Agents; Cells, Cultured; Collagen Type III; Female; Gene Expression; Gene

2015
Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors.
    British journal of pharmacology, 2008, Volume: 154, Issue:8

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; Atorvastatin; Drug Thera

2008
N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster.
    Antioxidants & redox signaling, 2008, Volume: 10, Issue:12

    Topics: Acetylcysteine; Amidines; Angiotensin II Type 1 Receptor Blockers; Animals; Benzylamines; Cardiomyop

2008
Effects of combination therapy with perindopril and losartan on left ventricular remodelling in patients with myocardial infarction.
    Clinical and experimental pharmacology & physiology, 2009, Volume: 36, Issue:7

    Topics: Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Losartan; Male; Middle Aged; Myo

2009
Noninvasive imaging of angiotensin receptors after myocardial infarction.
    JACC. Cardiovascular imaging, 2008, Volume: 1, Issue:3

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Binding Sites; Biomarkers; Disease

2008
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
    JACC. Cardiovascular imaging, 2009, Volume: 2, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopri

2009
Effect of early versus late AT(1) receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits.
    American journal of physiology. Heart and circulatory physiology, 2009, Volume: 297, Issue:1

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Colla

2009
Chronic central versus systemic blockade of AT(1) receptors and cardiac dysfunction in rats post-myocardial infarction.
    American journal of physiology. Heart and circulatory physiology, 2009, Volume: 297, Issue:3

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Echocardiography; Injections

2009
Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats.
    Acta physiologica (Oxford, England), 2010, Volume: 199, Issue:1

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis Regulatory Proteins; Cel

2010
Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction.
    Clinical and translational science, 2009, Volume: 2, Issue:6

    Topics: Animals; Antihypertensive Agents; Apoptosis; Cell Count; Cell Proliferation; Heart Ventricles; Inter

2009
Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy.
    Cancer research, 2010, Nov-15, Volume: 70, Issue:22

    Topics: Animals; Anti-Arrhythmia Agents; Antibiotics, Antineoplastic; Apoptosis; Cells, Cultured; Doxorubici

2010
Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels.
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Adrenal Glands; Aldosterone; Animals; Arrestins; beta-Arrestin 1; beta-Arrestins; Cell Line; Disease

2011
Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice.
    Journal of cardiovascular pharmacology, 2012, Volume: 59, Issue:3

    Topics: Animals; Cardiomegaly; Cardiotonic Agents; Cell Proliferation; Disease Models, Animal; Down-Regulati

2012
Cardiac remodeling and function following exercise and angiotensin II receptor antagonism.
    European journal of applied physiology, 2012, Volume: 112, Issue:8

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Hypertrophy, Left Ventricular; Los

2012
Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling.
    International journal of cardiology, 2013, Aug-20, Volume: 167, Issue:4

    Topics: Amides; Animals; Antihypertensive Agents; Aorta; Fumarates; Hypertension; Losartan; Male; Random All

2013
The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload.
    The Journal of steroid biochemistry and molecular biology, 2012, Volume: 132, Issue:3-5

    Topics: Animals; Aorta; Atrial Natriuretic Factor; Blood Pressure; Collagen Type III; Disease Models, Animal

2012
Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction.
    Journal of cellular and molecular medicine, 2012, Volume: 16, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcium-Binding Proteins; Cardiomegaly; Catecholam

2012
The functional role of the JAK-STAT pathway in post-infarction remodeling.
    Cardiovascular research, 2003, Volume: 57, Issue:1

    Topics: Angiotensin II; Animals; Anti-Arrhythmia Agents; Apoptosis; DNA-Binding Proteins; Janus Kinase 1; Ja

2003
[Contrast of losartan, fosinopril and amlodipine on cardiomyocyte apoptosis and left ventricular remolding in hypertensive rats].
    Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University, 2001, Oct-28, Volume: 26, Issue:5

    Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Cardiotonic Agents; Female; Fosinopril; Hyp

2001
[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats].
    Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University, 2001, Apr-28, Volume: 26, Issue:2

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Fibrosis; Fosinopril; Hypertension; Losartan; Male

2001
Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse.
    Clinical science (London, England : 1979), 2003, Volume: 104, Issue:2

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Collagen; Enala

2003
Comparative effects of carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats.
    Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:2

    Topics: Animals; Carbazoles; Carvedilol; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; He

2003
ST-segment resolution and late (6-month) left ventricular remodeling after acute myocardial infarction.
    The American journal of cardiology, 2003, Feb-15, Volume: 91, Issue:4

    Topics: Aged; Antihypertensive Agents; Coronary Circulation; Electrocardiography; Enalapril; Female; Humans;

2003
Adding angiotensin II type 1 receptor blockade to angiotensin-converting enzyme inhibition limits myocyte remodeling after myocardial infarction.
    Journal of cardiac failure, 2003, Volume: 9, Issue:3

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Female; Losarta

2003
Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor.
    Circulation, 2003, Aug-05, Volume: 108, Issue:5

    Topics: Age Factors; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Anima

2003
Comparison of the effects of losartan, enalapril and their combination in the prevention of left ventricular remodeling after acute myocardial infarction in the rat.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2002, Volume: 17, Issue:4

    Topics: Animals; Antihypertensive Agents; Drug Synergism; Enalapril; Female; Losartan; Myocardial Infarction

2002
Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors.
    Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:5

    Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym

2004
[Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction].
    Medicina, 2004, Volume: 64, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Fibrosis; Losartan; Myoca

2004
Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling.
    American journal of physiology. Heart and circulatory physiology, 2005, Volume: 288, Issue:4

    Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Blood Pressure;

2005
[Myocardial remodeling after experimental acute myocardial infarction in rats. Effect of renin-angiotensin-aldosterone blockade].
    Arquivos brasileiros de cardiologia, 2005, Volume: 84, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease

2005
[Comparative study of effects of fluvastatin and losartan on left ventricular remodeling in rat myocardial infarction].
    Zhonghua yi xue za zhi, 2005, Feb-16, Volume: 85, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; Drug Therapy, Combinatio

2005
[Blockade of renin-angiotensin system attenuates cardiac remodeling in rats undergoing aortic stenosis].
    Arquivos brasileiros de cardiologia, 2005, Volume: 84, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic V

2005
[Comparison of doxycycline, losartan, and their combination in the prevention of post-infarction remodeling in rats].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2005, Volume: 27, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Doxycycline; Female; Losartan; Myocardial Infarcti

2005
[Comparative effects of carvedilol, losartan and their combination in preventing left ventricular remodeling after acute myocardial infarction in rats].
    Zhonghua nei ke za zhi, 2001, Volume: 40, Issue:12

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Carbazoles; Carvedilo

2001
Losartan and acute myocardial infarction in insulin-resistant Zucker fatty rats: reduced ventricular arrhythmias and improved survival.
    Canadian journal of physiology and pharmacology, 2005, Volume: 83, Issue:11

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pressure; Gene Express

2005
[Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].
    Zhonghua yi xue za zhi, 2005, Nov-30, Volume: 85, Issue:45

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr

2005
Angiotensin II-induced sudden arrhythmic death and electrical remodeling.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:2

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Animals, Genetica

2007
Anabolic steroids induce cardiac renin-angiotensin system and impair the beneficial effects of aerobic training in rats.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:6

    Topics: Anabolic Agents; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C

2007
Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling.
    Circulation, 2008, Jan-22, Volume: 117, Issue:3

    Topics: Angiotensin II; Animals; Atrial Fibrillation; Cells, Cultured; Fibroblasts; Heart Atria; Humans; Los

2008
Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats.
    Cardiovascular research, 2008, Jun-01, Volume: 78, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Collagen; Combined Modality Therapy; Disease Model

2008
Both enalapril and losartan attenuate sarcolemmal Na+-K+-ATPase remodeling in failing rat heart due to myocardial infarction.
    Canadian journal of physiology and pharmacology, 2008, Volume: 86, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease

2008
Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction.
    Journal of cardiac failure, 1998, Volume: 4, Issue:3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Blood Flow Veloci

1998
Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.
    Proceedings of the National Academy of Sciences of the United States of America, 2000, Jan-18, Volume: 97, Issue:2

    Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Natriuret

2000
Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodelling in rats.
    Cardiovascular research, 2000, Volume: 46, Issue:1

    Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Losartan; M

2000
Effects of losartan on ventricular remodeling in experimental infarction in rats.
    Arquivos brasileiros de cardiologia, 2000, Volume: 75, Issue:6

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Hydroxyproline; Losartan; Ma

2000
Combined angiotensin converting enzyme inhibition and angiotensin AT(1) receptor blockade up-regulates myocardial AT(2) receptors in remodeled myocardium post-infarction.
    Cardiovascular research, 2001, Volume: 51, Issue:1

    Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; An

2001
Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling.
    Circulation, 2001, Jun-12, Volume: 103, Issue:23

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure;

2001
Comparative effects of losartan and captopril on ventricular remodeling and function after myocardial infarction in the rat.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 1998, Volume: 13, Issue:1

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Hear

1998
Effect of angiotensin type I-receptor blockade on left ventricular remodeling in pressure overload hypertrophy.
    Journal of cardiac failure, 2001, Volume: 7, Issue:4

    Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Disease Models, Animal; Echocardiography;

2001
Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure.
    Circulation, 2002, Mar-19, Volume: 105, Issue:11

    Topics: Angiotensins; Animals; Anti-Arrhythmia Agents; Calcium Signaling; Cardiomegaly; Cell Separation; Cel

2002